drugset / Trial / NCT06618651

A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors

NCT06618651

Phase 1 Recruiting 162 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.

Timeline

Start
2024-11-13
Primary completion
2026-01-01
Completion
2027-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-3821 Unknown

Indications

No indication recorded.